Healthcare Analyst

Wilfred Yuen

Healthcare analyst with 12+ years’ experience in both sell-side and buy-side leadership roles, with extensive experience IPO experience and a robust network of institutional investors and corporate executives. Coverage spans biopharma, biotech, CROs, devices, and health-tech stocks, delivered through with stock/sector/thematic reports, detailed financial models, and direct corporate access.

China Healthcare Weekly Wrap (13-17 July)

Akeso (9926.HK): SMMT 2Q26 Call Takeaways on Ivonescimab

China Healthcare Weekly Wrap (20-24 July)

China Healthcare Weekly Wrap (29 Jun - 3 July)

Jacobio (1167.HK): CEO Meeting Takeaways and Pipeline Updates/Analysis

China Healthcare Weekly Wrap (22-26 June)

Equity Bottom-Up

Sino Biopharmaceutical / Equity Bottom-Up

<ul>
<li>Today SBP (1177.HK) announced two deals today: 1) licensing out ex-China rights of PDE3/4 inhibitor TQC3721 to AstraZeneca; 2) obtained China sales right for two respiratory drugs from GSK</li>
<li>SBP will receive USD200m upfront from AstraZeneca (mgmt expects majority to recognise in 2H26); SBP expects c.RMB1bn incremental revenue from GSK's Trelegy Ellipta and Anoro Ellipta in China.</li>
<li>On future BD deals, SBP highlights key data readouts and registration study initiations in 2H26, as well as key upcoming IND filings. See below tables for details.</li>
</ul>


Today SBP (1177.HK) announced two deals today: 1) licensing out ex-China rights of PDE3/4 inhibitor TQC3721 to AstraZeneca; 2) obtained China sales right for two respiratory drugs from GSK
SBP will receive USD200m upfront from AstraZeneca (mgmt expects majority to recognise in 2H26); SBP expects c.RMB1bn incremental revenue from GSK's Trelegy Ellipta and Anoro Ellipta in China.
On future BD deals, SBP highlights key data readouts and registration study initiations in 2H26, as well as key upcoming IND filings. See below tables for details.


Sino Biopharm (1177.HK): Call Takeaways on BD Deals with AstraZeneca and GSK